Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The meeting are today and tomorrow. But the link is now down. http://www.councilka.org/summit/
Dr. Kim is in Washington DC this week for the Council of Korean Americans in our nation’s capital. http://www.councilka.org/summit/
Inovio Slide deck presentation from this week talks a lot about dmabs. 50+ antigens, partnerships etc.
http://ir.inovio.com/files/doc_presentations/2015/September/PP-150909-Rodman-Citi-final-PRINT.pdf
Inovio Pharmaceuticals Announces First Patient Dosed With Universal HIV Vaccine
http://ir.inovio.com/news/news-releases/news-releases-details/2015/Inovio-Pharmaceuticals-Announces-First-Patient-Dosed-With-Universal-HIV-Vaccine/default.aspx
Inovio is presenting at MERs conference in Korea on September 10th.
http://www.ivi.org/web/www/07_03?p_p_id=EXT_BBS&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&_EXT_BBS_struts_action=%2Fext%2Fbbs%2Fview_message&_EXT_BBS_messageId=803
Insider SIMON BENITO bought 6,000 shares on 8/14. Might be reason for pop?
http://d1lge852tjjqow.cloudfront.net/CIK-0001055726/a3097046-58a4-4891-9063-1603c5ab9bfe.pdf
Dr. Kim added 306,625 warranted/optioned shares @ $5.08. His family Now owns 3,654,924 shares
http://ih.advfn.com/p.php?pid=nmona&article=68005570&symbol=INO
Second Quarter 2015 Financial Results August 10, 2015 - 8:30 am http://www.investorcalendar.com/event/174125
Interesting Upcoming combo therapy presentation by Dr. Bagarazzi at Cancer Innovation Congress in October:
"Realising the promise of combination cancer immunotherapies"
• Politics and realities of Immunotherapy combination trial design
• Combinations of cancer vaccines and immune checkpoints
• Biomarkers to support combination immunotherapy
• Regulatory challenges in development of novel cancer combinations"
http://www.terrapinn.com/…/Cancer-innovation-c…/speakers.stm
http://www.terrapinn.com/template/live/documents/7511/16406#sthash.FGPpcMq7.dpbs
News for INO and partner on Ebola and MERS, reported by Partner VGXI.
http://vgxi.com/bbs/board.php?bo_table=b0601&wr_id=393
Translated :
Epicenter Life Sciences (KOSPI: 011000) was 9 days "in Houston specializing in international standard production facilities required for plasmid through the clinical VGXI Homers (MERS) has embarked on the production of DNA vaccines," he said.
Epicenter Life Sciences to develop a DNA vaccine that can prevent or cure Homers month with 27 days in the US NASDAQ listed company Inovio and had signed a joint research agreement, the US FDA in the second half of this year Homers DNA vaccine clinical trial approval It has said that the planning application.
Bakyounggeun epicenter Life Sciences said "after signing the contract for the last month Homers DNA vaccine development, clinical embarked on Homers DNA vaccines," said balhimyeo "Homers recent domestic support to governments and health officials to prevent the spread of the epidemic to spend, our company also hope to help spread Homers Jersey, "he said. "Homers undertaken to produce a DNA vaccine is also available today as a clinical emergency," said altitude.
In addition, the company said, "Preclinical research for Merck's DNA vaccine clinical development is completed all conditions, and then inoculated Homers DNA vaccines targeting the most similar in monkeys and humans preclinical study results pneumonia virus infection of Homers No confirmation was effectively eliminated the virus in the blood "and" geumbeon When production is completed clinical Homers DNA vaccines, clinical tests approved by the US Food and Drug Administration (FDA) is made to apply, "he said.
And so far it authorized vaccines and therapeutics Homers without conditions, or during the two vaccine products globally developed, the vaccine's efficacy proven in the epicenter Life Sciences animal testing has been completed to embark on clinical research and development. In particular, if the FDA in the United States as the Ebola virus, animal studies lieu rule (Animal Rule) to be applied to Homers DNA vaccines being developed geumbeon epicenter of life science, clinical development time to be shortened supply and permit fast The company is expecting.
Here is another abstract in for May https://immunology2015.zerista.com/poster/member/35437
American Society of Gene & Cell Therapy: ASGCT abstracts May 13 - 15 2015
http://www.abstracts2view.com/asgct/view.php?nu=ASGCT15L1_450
http://www.abstracts2view.com/asgct/view.php?nu=ASGCT15L1_453
http://www.abstracts2view.com/asgct/view.php?nu=ASGCT15L1_210
http://www.abstracts2view.com/asgct/view.php?nu=ASGCT15L1_417
http://www.abstracts2view.com/asgct/view.php?nu=ASGCT15L1_218
American Society of Gene & Cell Therapy: ASGCT abstracts May 13 - 15 2015
http://www.abstracts2view.com/asgct/view.php?nu=ASGCT15L1_450
http://www.abstracts2view.com/asgct/view.php?nu=ASGCT15L1_453
http://www.abstracts2view.com/asgct/view.php?nu=ASGCT15L1_210
http://www.abstracts2view.com/asgct/view.php?nu=ASGCT15L1_417
http://www.abstracts2view.com/asgct/view.php?nu=ASGCT15L1_218
I agree, that site hates INO, it would not surprise me. Good thing is that they don't have anything to do with efficacy or partnerships so in the end they will not damage Inovio PPS.
Ebola should be launching shortly and HIV will launch next quarter.
SPDR XBI Through 2/23 2,507,266
They bought another 40K shares yesterday and are at an all time high.
Well said guys. I think 2015 will be a major tipping point for INO in the positive direction. They will probably PR this conference this week. It sounds like INO is looking at Asian partnerships.
Vaccine World East Asia 2015 26 - 28 January 2015 | Seoul, South Korea
Formation of a Regional Vaccine Powerhouse & Winning Overseas Market Through Smart Strategic Partnerships
Confirmed Speaker: Dr. Joseph Kim, CEO, Inovio, Board of Trustee, International Vaccine Institute, Korea
•To synergize and capitalize on each other strengths to tap on opportunities in the global market
•Emphasis on the need to reduce competition between peers and to work together as a regional team
•Developing a niche market in Asia and working together in preparation for global pandemic
Developing a DNA Vaccine Against H5N1
Confirmed Speaker: Joseph Kim, CEO, Inovio, Board of Trustee, International Vaccine Institute, USA
•Superiority of an DNA influenza vaccine as compared to traditional developing methods
•Implications in the development & optimization of a DNA vaccine
•Future development and potential capability of DNA vaccine
Inovio HEP C partner Geneone
Therapeutic DNA Vaccine for Chronic Hepatitis C
Confirmed Speaker: Dr. Moonsup Jeong, R&D Director, GeneOne LifeScience, Korea
http://www.imapac.com/busines…/vaccine-world-east-asia-2015/
2015 should be a good year. We will see journal published HPV Phase II results. HIV launch with US government funding and the CEO said there will be some partnerships with Big Pharma. We also are waiting to find out about the ebola trial which is supposed to launch in January with Korean partner. We will also see Hepatitis C data with the Korean partner, Geneone. Be on the look out for gains in Korea. We could see some sort of hTERT, Aerodigestive, Head and Neck or Cervical cancer interim data, if good INO could make and hold gains. The Hepatitis B trial should start with Roche in 2015. Additionally I think we see the Monoclonal Antibody partnership with MedImmune and DARPA progress. Lastly, the Clostridium difficile (C. diff) DNA vaccine with Drexel/UPenn should gain some ground. Without a doubt, INO has a lot of irons in the fire.
Caveat - We could see dilution if INO goes alone for Phase III VGX.
Here is the fisrt quarter conference schedule:
Monday, January 12, 2015 Biotech Showcase San Francisco, California
Monday, January 26, 2015 Vaccine World East Asia 2015 South Korea
Monday, February 9, 2015 BIO CEO 2015 New York, New York
Tuesday, April 7, 2015 World Vaccine Congress - 2015
GL happy new year to all!
A solid add to the Team today.The newest member of INO helped commercialize zytiga. Zytiga is estimated at $2.3B a year in sales by 2018. This opens pathways for more Prostate cancer deals for INO.
http://ir.inovio.com/news/news-releases/news-releases-details/2014/Inovio-Pharmaceuticals-Appoints-Zane-Yang-MD-Vice-President-Clinical-Development-Oncology/default.aspx
I agree and GL to you guys too. It is definitely a long term play . But at this price it is a stable investment. I see it fluctuating 10-14 in the next few months until something "revolutionary" comes to fruition
New Journal article peer review. http://www.nature.com/gt/journal/vaop/ncurrent/full/gt201484a.html
Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells
Dr. Kim Interview 9/6/2014
We recently participated in the Fight Against Cancer campaign in which industry advocates, innovators and professionals provided information and resources regarding prevention, treatment and eventually the cure of cancer in the 21st century. In an interview with Inovio’s CEO Dr. J. Joseph Kim, he discussed the ability of DNA-based immune therapies to activate targeted T cell responses to kill cancer cells and why immunotherapies are positioned to become a powerful weapon in the war against cancer. Read the feature here: http://bit.ly/1oc47ma. The campaign was distributed through USA Today on Sept. 5th and is published online at www.futureofcancercare.com.
http://www.futureofcancercare.com/innovation-in-technology/advances-in-immunotherapy-offer-hope-in-war-against-cancer
Inovio Schedule
•September 8, 2014 Rodman & Renshaw 16th Annual Global Investment Conference
•September 11, 2014 Aegis Capital Healthcare & Technology Conference
• September 17, 2014 CANCER ANTIBODIES VACCINES/ADJUVANTS & DELIVERY
•September 26, 2014 4th International Conference on Vaccines & Vaccination
•October 6, 2014 Cancer Vaccines and Gene Therapy (CVGT) Meeting Monday,
•October 7, 2014 Bernstein's Oligo/Gene Therapeutics Event
•October 13, 2014 World Vaccine Congress 2014 Monday,
•October 28, 20143rd International Conference and Exhibition on Cell & Gene Therapy
•November 18, 2014 Stifel Healthcare Conference,
•December 2, 2014Piper Jaffray Healthcare Conference,
*****Cancer Vaccines and Gene Therapy (CVGT) Meeting (PA) - Phase II Efficacy Study Results*****
Day 1, MONDAY, 06 October 2014
8:30 - 9:00
*Late Breaking Presentation* Unknown company
11:30-12:00
Matthew Morrow, Immunology Lead, Inovio Pharmaceuticals
VGX-3100 HPV Specific Immunotherapy for Cervical Intraepithelial Neoplasia: Phase II Efficacy Study Results
Day 2, TUESDAY, 07 October 2014
8:30 - 9:00
*Late Breaking Presentation* Unknown company
10:30-11:00
Stephanie Ramos, Sr. Scientist, Inovio Pharmaceuticals
Enhancing DNA Vaccination by Intradermal and Intramuscular Electroporation
The 2014 CVGT meeting will be held at The Desmond in Malvern Pennsylvania is a one-of-a-kind hotel, conveniently located in one of Pennsylvania’s most scenic and historic settings.
Inovio vaccine. Drexel researchers make progress on DNA vaccine targeting bacterial toxin
Pfizer also studying C. Diff. Potential partnership.
http://www.newsworks.org/index.php/local/item/71038-drexel-researchers-make-progress-on-dna-vaccine-targeting-bacterial-toxin?linktype=hp_topstory
Hows the Panel and awards going out there?
The Immunotherapies and Vaccine Summit - 2014 - Boston, MA
Tuesday August 12
4:15 Engineering Cancer Immunotherapy One (DNA) Sequence at
a Time Mark Bagarazzi, M.D., CMO, Inovio Pharmaceuticals
Inovio is developing cancer immunotherapeutics by targeting both viral oncogenes (HPV E6, E7) as well as self proteins associated with cancer progression and metastases (PSA, PSMA, hTERT). Our common approach involves enhancing the delivery of optimized DNA sequences with the use of our proprietary in vivo electroporation system. We will share both preclinical and clinical data regarding several cancer indications.
Wednesday, August 13
7:45 am Breakfast Presentation (Sponsorship Opportunity Available)
or Morning Coffee
PREDICTING & ENHANCING HUMAN RESPONSE
8:25 Chairperson’s Opening Remarks
Mark Bagarazzi, M.D., CMO, Inovio Pharmaceutical
http://www.imvacs.com/uploadedFiles/ImVACS/Agenda/14/2014-IMT-Brochure.pdf
3:00 Synthetic DNA Vaccines for Difficult Targets
David B. Weiner, Ph.D., Professor, Pathology and Laboratory Medicine, Chair, Gene Therapy and Vaccine Program, CAMB, University of Pennsylvania Perelman School of Medicine
Through multiple improvements including synthetic plasmid optimization, genetic adjuvant technology further combined with enhanced EP delivery, we now report a platform for vaccine/immune therapeutic development with major relevance to human disease settings. These combined DNA approaches drive
immune responses similar or superior to live viral vector protocols in important model systems including HIV, HPV therapy, Influenza among others. We will
present data that illuminate specific features of these synthetic DNA vaccines and benchmark their performance in animal models and in human studies.
Reverse Split passed. It is very dissapointing that Dr. Kim could not get the PPS up "organically" as he stated in 2013. I believe all they will do is dilute more shares. We will see.
HEP C News from INO affiliate in Korea:
VGX Inter (KOSPI: 011000) "Over the past 22 days, Keimyung University School of Medicine opened in 2014 between the Association for Single Topic Symposium Proceedings of the company through the research and development of DNA vaccines in the treatment of chronic hepatitis C (VGX-6150) for clinical research content was introduced, "he said.
Recent advances in the treatment of viral hepatitis, the theme of the symposium conducted geumbeon heojeong professor at Pusan ??National University College of Medicine, Section of new chronic hepatitis C treatment, a therapeutic vaccine (VGX-6150) entitled "Current progress in using electric drilling machines VGX-6150 DNA vaccine therapy clinical trial for safety evaluation for Phase 1 multicenter, open, progress in the form of increased capacity, the new treatment of chronic hepatitis C is the expectation, "he said.
Professor heojeong announcement, "VGX International clinical trials being developed in the treatment of chronic hepatitis C DNA vaccine (VGX-6150) is the most difficult to treat existing standard treatments first genotypes (1a, 1b) of the amino acid sequence of the virus database analyzing the antigen within the amino acid common sequence to find and enhanced the maximum concordance between the virus, antigens for inducing immune responses to a wide range of amino acid sequences were selected as "high balhimyeo" Thus produced DNA vaccine (VGX-6150) is 1000 times the incidence antigen, the immune response induced by 100-fold increase in the electroporation method has the characteristics of high efficiency, the body passed to the already confirmed non-clinical safety and efficacy in a bar, "he said.
Inter VGX DNA vaccine treatment of chronic hepatitis C (VGX-6150) of the hepatitis C virus NS3/4A, NS4B, NS5A antigen and adjuvant for the expression of IL-28B and a plasmid containing a mixture of nucleic acid sequences, the antigen -specific T cell immune response by inhibiting the replication of hepatitis C virus or hepatitis C virus-infected hepatocytes is removed.
People infected with the hepatitis C virus all over the world as of 2005 about 2.8 percent of the approximately 185 million people are estimated to Central Asia, including Mongolia, China, Pakistan, Thailand and elsewhere in Southeast Asia, Egypt wisihan North Africa is relatively often infected.
Treatment of chronic hepatitis C $ 3 billion global market scale in 2012, but now has $ 20 billion in 2020 and is forecast to grow to scale, such as a recent DAA, even if treated with the antiviral drug interferon resistance by conventional formulations tend to come back again , no side effects, such as hepatitis C DNA vaccine treatment of autoimmune therapeutics are emerging as clinical need.
http://www.vgxi.com/bbs/bbs/board.php?bo_table=news&wr_id=344
IMO. The big boys have loaded up at these low prices , or are almost there, and will finally let INO run. Here is a confrence schedule for INO and the upcoming catalysts.
Catalysts:
•Cervical Dysplasia Therapeutic Mid-2014 Phase II study data
•ROCHE Partnership - Prostate Cancer Therapeutic 1H 2014 Initiate phase I/II
•Cervical Cancer Therapeutic 1H 2014 Initiate phase I/II trial
•Head & Neck Cancer Therapeutic 1H 2014 Initiate phase I/II trial
•HIV Preventive/Therapeutic 1H 2014 Initiate PENNVAX-GP
•Influenza Preventive phase I study Seeking grant funding
•Hepatitis C Therapeutic 2015 Report phase I study data
•Malaria Preventive 2014 Initiate phase I/IIa
•ROCHE Partnership - Hepatitis B Therapeutic 2014 Prepare phase I/IIa
•Breast & Lung Cancers Initiate phase I/IIa hTERT Universal Cancer vaccine
•In development: MERS , Dengue Fever, H79N,
•Advancing discussions with large pharmaceutical companies.
CONFERENCES
• World Vaccine Congress 2014
Monday, March 24, 2014
Washington, District of Columbia in Washington, District of Columbia
• PARTNERSHIPS IN CLINICAL TRIALS 2014 SPEAKER FACULTY
Las Vegas, Nevada in Las Vegas, Nevada 3/30 to 4/2
• Inovio AACR Conference April 5-9, 2014 San Diego
San Diego, California in San Diego, California
• IMMUNOPOTENTIATORS IN MODERN VACCINES Portugal Wednesday, May 7, 2014
• Inovio Sponsor - ASGCT Friday, May 30, 2014
Washington, District of Columbia in Washington, District of Columbia
• ASCO - Possible HPV results 5/30 to 6/3
Chicago, Illinois in Chicago, Illinois
• CANCER ANTIBODIES VACCINES/ADJUVANTS & DELIVERY
Switzerland
Wednesday, September 17, 2014
GNBT can easily dip back into the .02s. They have a ton of toxic warrants to go through. So I don't know if I would buy at these levels unless you are looking for a quick flip on a pump article. At $.026ish yes a buy.
I have to agree with beststock and groe on that matter.
Its funny you call everyone out but have never revealed you identity...SO who are you? if you are so tough.
Wow this board has been turned into the spamathon Yahoo message board. Reporting for personal attacks, violation of privacy off topics etc.
But hey I agree, GNBT is a joke, but they are still presenting at ASCO. THey need to go bankrupt or AE37 taken over.
Post removed for blatant lying with intentions of misleading others.
March 24 - 26 2014 ViE Awards Shortlist http://www.terrapinn.com/conference/world-vaccine-congress-washington/awards.stm
INOVIO
Link to conference presentation. http://wsw.com/webcast/cowen16/INO/
Lots of good highlights. My favorite
"We will have by the end of this year the largest arsenal of active cancer antigen weapons against multiple cancer types, more than anyone else in this field, this is out Master Plan."
Remember tax implication when selling Inovio stock. I could sell my INO shares right now and hope for it to drop and buy back later but I will lose my long position (over a year) where I pay 15% in capital gains taxes. If INO gets bought out by next January you are looking at 40% taxes (short position) losing $100k+ versus making a quick $10-20k. Just a thought.
Thank for your posts too, it helped me with DD. I remember buying in the $.50 s too. What a roller coaster!
I agree, Inovio doesn't make ipods or planes or cars where you can accurately predict volumes based on sales and fundamentals.
Look at Intercept Pharmaceuticals Inc, it went from $75 to $445 in 1 day.
If people could predict that movement then they would be billionaires.
GLTU but Inovio isn't a chart stock to us long term holders. If it were everyone would have seen these moves and be multi millionaires off of INO in the last month alone. Inovio moves to us based on catalysts, which starts next Monday presentation at the Cowen and Company 34th Annual Health Care Conference. INO surprises everyone. We have done our DD and say sell with caution...
So Here is why INO is up.
CEO Dr. Kim said INO will be the next Amgen or Gilead which would put INO between $400 and $600 per share.
Catalysts: 1st Half 2014
1. VGX-3100 results - Mid-2014 Cervical dysplasia Phase II study data
2. INO-3112 - Cervical Cancer 1H 2014 Initiate phase I/IIa
3. INO-3112 - Head and Neck Cancer 1H 2014 Initiate phase I/IIa
4. Prostate Cancer - initiate trial with Partner Roche
5. Initiate PENNVAX-GP phase I study
2014 2nd Half:
1. Initiate hTERT trials for:
a. Lung cancer
b. breast cancer
c. Pancreatic cancer
2. Initiate HEP B - initiate trial with Roche
3. Initiate Malaria trials
Other potential catalysts:
MERS, FLU, MRSA, Chikungunya virus, and Dengue fever.
World Vaccine Conference 2014
World's Largest Vaccine Conference & Expo March 24th-26th 2014 in Washington D.C.
Speakers list:
Dr. Sardesai Chief Operating Officer
Day 2 - March 25 @ 11.45 Cancer immunotherapy – Prospects for expanding the standard of care in HPV associated disease
@ 14.25 Using synthetic DNA vaccines to induce strong antibody and T-cell responses
http://www.terrapinn.com/conference/world-vaccine-congress-washington/speaker-niranjan-SARDESAI.stm
Also, Dr. Anthony Ford Hutchinson of Inovio Scientific Advisory Board is speaking.
Day 2 - March 25 @ 10.49
Chairman's remarks
Day 3 - March 26@ 11.29
Chairman's remarks @ 11.55
Use of Innovative technologies to address unmet needs for vaccines for viral diseases
http://www.terrapinn.com/conference/world-vaccine-congress-washington/speaker-anthony-FORDHUTCHINSON.stm
He can be seen in Inovio's latest video:
GLTU too! I know there will be pull backs I agree with you on that 1. I hope everyone gets some going into the results, and before it skyrocket. THere will be grants partnerships along the way. GL:)
Ah yes another know it all. Sorry, Inovio will be rising going into results. Get on the train or be left at the station.